Table 2.
Ov gene ID | Function of family | Drugs (WHO name) | ATC level 3 classification |
---|---|---|---|
OVOC2713 | Ribonucleotide reductase, small chain | Fludarabine phosphate, clofarabine, gemcitabine, (hydroxyurea), gallium nitrate | Antimetabolites, other antineoplastic agents. |
OVOC11146 | Calcineurin-like phosphoesterase | Tiagabine | Antiepileptics |
OVOC215 | Sodium neurotransmitter symporter family | Imipramine, clomipramine, amitriptyline, nortriptyline, protriptyline, amoxapine, fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram, trazodone, nefazodone, venlafaxine, milnacipran, duloxetine, desvenlafaxine, vilazodone, vortioxetine, (levomilnacipran, chlorphentermine) | Antidepressants (unclassified) |
OVOC3747 | Ion transport protein | Dronedarone, (nimodipine, felodipine) | Antiarrhythmics, class I and III (selective calcium channel blockers with mainly vascular effects) |
OVOC1986 | KQT-1 potassium channel | Dronedarone | Antiarrhythmics, class I and III |
OVOC1111 | Receptor family ligand binding region | Baclofen, oxybate | Muscle relaxants, central acting agents, null |
OVOC5191 | G-protein coupled GABA receptor activity | ||
OVOC12632 OVOC12637 OVOC12635 OVOC968 |
NADH-ubiquinone oxidoreductase chains 1, 4 and 5; probable NADH dehydrogenase [ubiquinone] iron-sulfur protein 7 | Metformin | Blood glucose lowering drugs excluding insulin |
OVOC6309 | 3-oxo-5-α-steroid 4-dehydrogenase | Dutasteride | Drugs used in benign prostatic hypertrophy |
OVOC10592 | ERG2 and sigma1 receptor like protein | Pentazocine, (dextromethorphan) | Opiods, cough suppressants (other nervous system drugs) |
OVOC8585 | C-terminal tandem repeated domain in type 4 procollagen | Xiaflex, (ocriplasmin) | Other drugs for disorders of the musculoskeletal system (other ophthalmologicals) |
OVOC10695 | Glycosyl transferase family 21 | Miglustat, eliglustat | Other alimentary tract and metabolism products |
OVOC4110 | Amidase | Acetaminophen | Other analgesics and antipyretics |
The table shows anatomical therapeutic classification groups for drugs identified as potential repurposing candidates. For drugs in parentheses, the mechanism is shown in similar style parentheses in the ‘ATC level 3 classification’ column.